Coronavirus company news summary - Lilly to supply more doses of antibody cocktail to US in $1.29bn deal - NRx reports positive safety data in Phase III trial of Covid-19 treatment
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Lilly to supply more doses of antibody cocktail to US in $1.29bn deal – NRx reports positive safety data in Phase III trial of Covid-19 treatment

03 Nov 2021

Eli Lilly has signed an agreement to supply additional doses of its Covid-19 combination therapy, bamlanivimab with etesevimab, to the US Government. Under the $1.29bn deal, Lilly will deliver 614,000 doses of the neutralising antibody cocktail by 31 January 2022. At least 400,000 of these doses will be delivered by end of 2021, the company said. Administered together, the cocktail has received Emergency Use Authorization in the US to treat mild to moderate Covid-19 infection or for disease prevention post-exposure in some people.

NRx Pharmaceuticals has reported that the treatment with Zyesami (aviptadil) posed no novel safety concerns in the US National Institutes of Health-sponsored Phase III ACTIV-3b Critical Care clinical trial. The Independent Data Safety Monitoring Board (DSMB) of the trial carried out the third scheduled assessment and reported no new safety concerns linked to Zyesami on reviewing over 300 subjects. The DSMB also advised advancing subject enrolment in the trial.

The US Centers for Disease Control and Prevention (CDC) have recommended inoculating children aged five to 11 years with the Pfizer and BioNTech’s Covid-19 vaccine. In a media statement, CDC director Rochelle Walensky endorsed the CDC Advisory Committee on Immunization Practices’ previous recommendation of the shot in children of this age group.